Research programme: thymic cell therapies - LyGenesis
Latest Information Update: 22 Mar 2021
At a glance
- Originator LyGenesis
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological disorders